Literature DB >> 18656809

Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.

Ryujiro Sugimoto1, Atsunori Nakao, Masaomi Yamane, Shinichi Toyooka, Megumi Okazaki, Motoi Aoe, Kuniaki Seyama, Hiroshi Date, Takahiro Oto, Yoshifumi Sano.   

Abstract

In this study we report the case of a 28-year-old female patient with recurrent lymphangioleiomyomatosis (LAM) in the allografts after bilateral living-donor lobar lung transplantation. Although her post-operative course under immunosuppression with tacrolimus and prednisolone had been uneventful without rejection episodes, she had developed shortness of breath and a progressive chylous effusion with diffuse cystic changes in both lungs 5 years after transplantation. In spite of a diagnosis of having a recurrence of LAM based on radiologic findings and deteriorating pulmonary function, her clinical symptoms, which included dyspnea and chylothorax, were significantly improved after treatment with sirolimus. Although a beneficial effect of sirolimus in the treatment of LAM has not been definitively determined, this report may provide useful information for management of recurrent LAM after lung transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18656809     DOI: 10.1016/j.healun.2008.05.012

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

1.  Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation.

Authors:  Khawaja S Zaki; Zahra Aryan; Atul C Mehta; Olufemi Akindipe; Marie Budev
Journal:  World J Transplant       Date:  2016-03-24

2.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

Review 3.  Optimizing treatments for lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Rev Respir Med       Date:  2012-06       Impact factor: 3.772

Review 4.  Recurrence of primary disease following lung transplantation.

Authors:  Dorina Rama Esendagli; Prince Ntiamoah; Elif Kupeli; Abhishek Bhardwaj; Subha Ghosh; Sanjay Mukhopadhyay; Atul C Mehta
Journal:  ERJ Open Res       Date:  2022-05-30

5.  Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.

Authors:  Jared Klarquist; Allison Barfuss; Sridhar Kandala; Mary J Reust; Ruedi K Braun; Jennifer Hu; Daniel F Dilling; Mark D McKee; Raymond E Boissy; Robert B Love; Michael I Nishimura; I Caroline Le Poole
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

6.  Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis.

Authors:  Claire M Ellender; Trevor J Williams; Julian Gooi; Gregory I Snell; Helen M Whitford
Journal:  Respirol Case Rep       Date:  2015-05-18

Review 7.  Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.

Authors:  Filipe Palavra; Conceição Robalo; Flávio Reis
Journal:  Oxid Med Cell Longev       Date:  2017-03-12       Impact factor: 6.543

Review 8.  Recent advances in the management of lymphangioleiomyomatosis.

Authors:  Kai-Feng Xu; Xinlun Tian; Jay H Ryu
Journal:  F1000Res       Date:  2018-06-18

9.  mTOR Inhibitors in Tuberous Sclerosis Complex.

Authors:  Paolo Curatolo; Romina Moavero
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

10.  Lung Transplantation for Lymphangioleiomyomatosis in Japan.

Authors:  Katsutoshi Ando; Yoshinori Okada; Miki Akiba; Takashi Kondo; Tomohiro Kawamura; Meinoshin Okumura; Fengshi Chen; Hiroshi Date; Takeshi Shiraishi; Akinori Iwasaki; Naoya Yamasaki; Takeshi Nagayasu; Masayuki Chida; Yoshikazu Inoue; Toyohiro Hirai; Kuniaki Seyama; Michiaki Mishima
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.